Foreign drugs and vaccines makers Sanofi and GSK plan to seek marketing approval for their jointly developed Covid vaccine in India and intend to submit data from both its booster and Phase 3 efficacy trials as the basis for regulatory applications. According to the companies, in the VAT08 Phase 3 primary series trial, two doses of this vaccine in seronegative populations demonstrated  100 percent efficacy against severe COVID-19 disease and hospitalizations;  75 percent efficacy against moderate or severe disease; and 57.9 percent efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern